STOCK TITAN
  1. Home
  2. News
  3. LIAN

LianBio (LIAN) Stock News, Jun-Oct 2023

LIAN Nasdaq
News

LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
117.27%
Tags
none
-
News

LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.63%
Tags
clinical trial
-
News

LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
earnings
News

LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.94%
Tags
clinical trial
-
News

LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
fda approval
-
News

LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and Thailand

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.2%
Tags
none
News

LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
clinical trial
-
News

LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
none
-
News

LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.88%
Tags
none
News

LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
clinical trial